These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 21909982)

  • 1. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
    Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
    Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
    Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
    Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells.
    Azuma K; Urano T; Horie-Inoue K; Hayashi S; Sakai R; Ouchi Y; Inoue S
    Cancer Res; 2009 Apr; 69(7):2935-40. PubMed ID: 19318565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
    Sui M; Huang Y; Park BH; Davidson NE; Fan W
    Cancer Res; 2007 Jun; 67(11):5337-44. PubMed ID: 17545614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
    Saji S; Kawakami M; Hayashi S; Yoshida N; Hirose M; Horiguchi S; Itoh A; Funata N; Schreiber SL; Yoshida M; Toi M
    Oncogene; 2005 Jun; 24(28):4531-9. PubMed ID: 15806142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells.
    Reizner N; Maor S; Sarfstein R; Abramovitch S; Welshons WV; Curran EM; Lee AV; Werner H
    J Mol Endocrinol; 2005 Aug; 35(1):135-44. PubMed ID: 16087727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.
    Jin Y; Hu W; Liu T; Rana U; Aguilera-Barrantes I; Kong A; Kumar SN; Wang B; Gao P; Wang X; Duan Y; Shi A; Song D; Yang M; Li S; Han B; Zhao G; Fan Z; Miao QR
    Cancer Lett; 2018 Apr; 419():233-244. PubMed ID: 29373839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel.
    Czeczuga-Semeniuk E; Jarzabek K; Lemancewicz D; Wołczyński S
    Gynecol Endocrinol; 2009 May; 25(5):287-93. PubMed ID: 19340624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells.
    Zhao C; Matthews J; Tujague M; Wan J; Ström A; Toresson G; Lam EW; Cheng G; Gustafsson JA; Dahlman-Wright K
    Cancer Res; 2007 Apr; 67(8):3955-62. PubMed ID: 17440111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes.
    Moggs JG; Murphy TC; Lim FL; Moore DJ; Stuckey R; Antrobus K; Kimber I; Orphanides G
    J Mol Endocrinol; 2005 Apr; 34(2):535-51. PubMed ID: 15821115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
    Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
    Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer.
    Yoshimoto N; Toyama T; Takahashi S; Sugiura H; Endo Y; Iwasa M; Fujii Y; Yamashita H
    Breast Cancer Res Treat; 2011 Nov; 130(1):331-9. PubMed ID: 21755340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
    Chong K; Subramanian A; Sharma A; Mokbel K
    Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
    Travaglini L; Vian L; Billi M; Grignani F; Nervi C
    Int J Biochem Cell Biol; 2009 Jan; 41(1):225-34. PubMed ID: 18789398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
    Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH
    Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.